Thinking outside the cranium

Anahita Sadeghi¹, Behrouz Navabakhsh¹, Leila Aghaghazvini²

¹ Department of Internal Medicine, School of Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
² Department of Radiology, School of Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Keywords
Cerebral Toxoplasmosis, Human Immunodeficiency Virus, Eccentric Target Sign, Magnetic Resonance Imaging

Introduction
Cerebral toxoplasmosis is a leading cause of central nervous system (CNS) lesions in severely immunocompromised human immunodeficiency virus+ (HIV+) patients who are seropositive for the parasite and have not received effective chemoprophylaxis. A 48-year-old HIV+ woman presented to our emergency room with seizure and decreased level of consciousness. She had developed fever, productive cough, and malaise 1 week prior to her current admission. Multifocal sensory and motor deficits in her extremities were revealed on neurologic examination. The brain imaging of our patient showed a distinctive ring-enhancing lesion that narrowed our differential diagnosis considerably.

The patient was admitted on January 20, 2009 with decreased level of consciousness, urinary incontinence, upward eye deviation, right arm tonic flexion and right leg clonic jerks while the left extremities were tonically extended. Her seizure was controlled with intravenous diazepam and phenytoin, and she was fully conscious for history taking 5 h after presentation.

The patient had a positive history for HIV infection and reported prolonged close contact with a known tuberculosis (TB) case 2 years ago. She had developed fever, productive cough and malaise 1 week prior to her current admission; CD4 count of 18 cells/µL, skin purified protein derivative reactivity of 5 mm and a negative sputum smear for acid-fast bacilli had been reported at the time waiting for culture results. She also complained of headaches and weight loss during the past month. Oral co-amoxiclav and co-trimoxazole were administered for her recent symptoms. For her HIV, she had received IMOD intermittently (for a total of 6 months) during the year prior to admission – Setarud (IMOD) is a herbal medicine prepared from a mixture of extracts of Rosa canina, Urtica dioica, and Tanacetum ulgare in addition to selenium, flavonoids, and carotenes. Ten years ago, after a bout of jaundice, she had been diagnosed with acute hepatitis B. The resolution of which was documented with hepatitis B surface antigen clearance and hepatitis B surface antibody seroconversion at the time.

Neurologic examination revealed multifocal sensory and motor deficits involving her left ulnar nerve distribution, right median nerve distribution, proximal and distal right lower extremity weakness and atrophy, and symmetric sensory deficits in both feet. The patient’s lab data during the past year revealed a steady decline in CD4 counts from 361 cells/µL in August 2007 and variable peripheral eosinophilia. The patient’s lab results during her admission are shown in table 1. Brain imaging showed a single ring-enhancing lesion in the left posterior parietal lobe (Figure 1).

In developing countries, the differential diagnosis for a severely immunocompromised HIV+ patient with a solitary ring-enhancing brain lesion should include primary CNS lymphoma (PCNSL), TB, toxoplasmosis, neurocysticercosis, and much less commonly infections caused by Staphylococcus, Streptococcus, Salmonella, Aspergillus, Nocardia, Rhodococcus, Listeria, Cryptococcus, Treponemapallidum, and cytomegalovirus (CMV).

The typical magnetic resonance finding in toxoplasmic encephalitis (TE) is that of multiple ring-enhancing lesions with a predilection for basal ganglia; solitary lesions are reported in approximately 30% of cases.¹ Single and multiple lesions are equally
common in patients with PCNSL and because of the inadequacy of neuroradiological features to distinguish between TE and PCNSL, a high suspicion for the latter should be maintained throughout the follow-up of a presumed TE patient with a solitary CNS lesion – especially for lesions that are larger than 4 cm. The “eccentric target sign” in post-contrast T1-weighted magnetic resonance imaging (MRI) has been proposed as a highly characteristic feature found in 30% of biopsy proven cerebral toxoplasmosis cases. This imaging feature is more commonly found in cortical-based toxoplasmosis abscesses organizing around a cerebral sulcus with the eccentric core representing the inflamed cerebral vessels traversing that sulcus. Neurocysticercosis can produce a similar ring-enhancing lesion with an eccentric hyperdense nodule representing the scolex of the live tapeworm, but the parasite cysts in this stage of development can usually be differentiated from an abscess by the absence of diffusion restriction within the cyst in diffusion-weighted imaging and minimal parenchymal edema surrounding the lesion; in addition, Taenia solium infections are extremely rare in Iran.

Empiric treatment for TE as the most probable cause of the patient’s CNS lesion was begun with pyrimethamine, sulfadiazine, and leucovorin. Highly active antiretroviral therapy for her HIV infection and isoniazid for her TB infection were also initiated as well as co-trimoxazole and azithromycin for Pneumocystis jiroveci pneumonia and Mycobacterium avium complex prophylaxis. HIV infection by itself was identified as the probable cause of the patient’s eosinophilia.

Table 1. Laboratory data

| Variable                  | Reference range | January 22nd, 2009 |
|---------------------------|-----------------|--------------------|
| White cell count (per mm³) | 4000-11,000     | 6800              |
| Differential count (%)    |                 |                    |
| Neutrophils               | 40-70           | 46                |
| Lymphocytes               | 22-44           | 43                |
| Monocytes                 | 2-10            | 2                 |
| Eosinophils               | 0-8             | 9.8               |
| Basophils                 | 0-3             | 0                 |
| Hemoglobin (g/dL)         | 13-16 (women)   | 9.8               |
| Platelet count (per mm³)  | 150,000-450,000 | 318,000           |
| ESR (mm/h)                | 0-15            | 45                |
| CRP (mg/L)                | < 10            | 160               |
| ALT (IU/L)                | Up to 38        | 10                |
| AST (IU/L)                | Up to 40        | 12                |
| ALP (IU/L)                | 80-306          | 105               |
| INR                       | 1-1.2           | 1.1               |
| PTT (s)                   | 25-35           | 22                |
| Urea (mg/dL)              | 7-21            | 27                |
| Creatinine (mg/dL)        | 0.7-1.4         | 1.1               |
| LDH (IU/L)                | Up to 480       | 317               |
| Blood sugar (mg/dL)       | Up to 140       | 110               |
| Calcium (mg/dL)           | 8.5-10.5        | 9.6               |
| Phosphorus (mg/dL)        | 2.5-5           | 3.1               |
| Sodium (meq/L)            | 135-145         | 139               |
| Potassium (meq/L)         | 3.5-5           | 4.7               |
| VDRL                      | Negative        |                    |
| Toxoplasma IgG            | Positive        |                    |
| Toxoplasma IgM            | Negative        |                    |
| CMV IgG                   | Positive        |                    |
| Anti-HBs                  | Negative        |                    |
| HBsAg                     | Negative        |                    |
| Anti-HCV                  | Negative        |                    |

ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; ALT: Alanine transaminase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; INR: International normalized ratio; PTT: Partial thromboplastin time; LDH: Lactate dehydrogenase; VDRL: Venereal Disease Research Laboratory; IgG: Immunoglobulin G; IgM: Immunoglobulin M; CMV: Cytomegalovirus; Anti-HBs: Hepatitis B surface antibody; HBsAg: Hepatitis B surface antigen; HCV: Hepatitis C virus.
Despite being rare, CMV infection can present as ring-enhancing lesions in severely immunocompromised HIV patients and because of the presence of mononeuropathy multiplex in this patient was considered a possibility. Since PCNSL, TB, and CMV could not be definitely ruled out, a follow-up MRI after 2 weeks of empirical therapy was planned. Our patient responded favorably to the initial empiric therapy thus consolidating a diagnosis of cerebral toxoplasmosis.

**Conclusion**
The most probable diagnosis of cerebral lesion in HIV positive patients is cerebral toxoplasmosis and in resource poor settings for cerebral biopsy, the patients can be treated according to radiographic and laboratory findings.

**Conflict of Interests**
The authors declare no conflict of interest in this study.

**How to cite this article:** Sadeghi A, Navabakhsh B, Aghaghazvini L. Thinking outside the cranium. Iran J Neurol 2014; 13(3): 188-90.

---

**Figure 1.** T1-weighted magnetic resonance imaging with gadolinium enhancement shows a single 1.5 cm targetoid lesion with ring enhancement and parenchymal vasogenic edema surrounding the lesion in the left posterior parietal lobe

**References**

1. Ho YC, Sun HY, Chen MY, Hsieh SM, Sheng WH, Chang SC. Clinical presentation and outcome of toxoplasmic encephalitis in patients with human immunodeficiency virus type 1 infection. J Microbiol Immunol Infect 2008; 41(5): 386-92.
2. Ramsey RG, Gean AD. Neuroimaging of AIDS. I. Central nervous system toxoplasmosis. Neuroimaging Clin N Am 1997; 7(2): 171-86.
3. Kumar GG, Mahadevan A, Guruprasad AS, Kovoor JM, Sathishandra P, Nath A, et al. Eccentric target sign in cerebral toxoplasmosis: neuropathological correlate to the imaging feature. J Magn Reson Imaging 2010; 31(6): 1469-72.
4. Yeaney GA, Kolar BS, Silberstein HJ, Wang HZ. Case 163: solitary neurocysticercosis. Radiology 2010; 257(2): 581-5.
5. Sivaram M, White A, Radcliffe KW. Eosinophilia: clinical significance in HIV-infected individuals. Int J STD AIDS 2012; 23(9): 635-8.